INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $198,500 | 0.0% | 200,000 | 0.0% | 0.00% | – |
| Q1 2023 | $198,500 | +1.5% | 200,000 | 0.0% | 0.00% | – |
| Q4 2022 | $195,641 | -99.9% | 200,000 | 0.0% | 0.00% | – |
| Q3 2022 | $192,830,000 | -36.9% | 200,000 | -37.9% | 0.00% | – |
| Q1 2022 | $305,476,000 | -0.3% | 322,000 | 0.0% | 0.00% | – |
| Q4 2021 | $306,274,000 | -35.1% | 322,000 | -38.3% | 0.00% | – |
| Q3 2021 | $472,052,000 | -98.5% | 522,000 | -98.5% | 0.00% | -100.0% |
| Q2 2021 | $31,606,260,000 | +9.5% | 35,000,000 | 0.0% | 0.01% | +7.7% |
| Q1 2021 | $28,860,650,000 | +4.6% | 35,000,000 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $27,598,900,000 | +7.2% | 35,000,000 | +9.4% | 0.01% | -7.1% |
| Q3 2020 | $25,745,920,000 | -31.0% | 32,000,000 | -36.0% | 0.01% | -39.1% |
| Q2 2020 | $37,300,000,000 | -11.9% | 50,000,000 | -4.8% | 0.02% | -23.3% |
| Q1 2020 | $42,323,295,000 | +31.4% | 52,500,000 | +64.1% | 0.03% | +50.0% |
| Q4 2019 | $32,209,920,000 | +289011.6% | 32,000,000 | +156.0% | 0.02% | +66.7% |
| Q4 2016 | $11,141,000 | -75.5% | 12,500,000 | -69.1% | 0.01% | -75.5% |
| Q3 2016 | $45,425,000 | – | 40,500,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Man Investments (CH) AG | 3,300,000 | $2,640,000 | 2.48% |
| SYMPHONY ASSET MANAGEMENT LLC | 14,000,000 | $11,200,000 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 36,000,000 | $28,879,000 | 1.14% |
| Opera Trading Capital | 5,500,000 | $4,344,000 | 0.89% |
| MACKAY SHIELDS LLC | 17,789,000 | $14,221,000 | 0.52% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 24,415,000 | $19,539,000 | 0.37% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 6,000,000 | $4,918,000 | 0.37% |
| OAKTREE CAPITAL MANAGEMENT LP | 28,415,000 | $22,732,000 | 0.36% |
| GLG Partners LP | 8,700,000 | $6,960,000 | 0.33% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 42,285,000 | $33,828,000 | 0.28% |